Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Diagnostic and Therapeutic Uptake of Intrathyroid Metastasis of Midgut Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE Imaging

Vija Racaru, Lavinia, PhD, MD*; Sinigaglia, Mathieu, MD; Fontaine, Sebastien, MD*‡; D'Aure, Dominique, MD§; Courbon, Frederic, MD, PhD*; Dierickx, Lawrence, MD, PhD*

doi: 10.1097/RLU.0000000000002586
Interesting Images

A 58-year-old woman with 5-year history of grade 1 progressive metastatic intestinal neuroendocrine tumor with metachronous liver metastases initially treated by surgery and liver embolization underwent 68Ga-DOTANOC PET/CT before 177Lu-DOTATATE therapy. 68Ga-DOTANOC PET/CT revealed increased uptake in several liver metastases and right iliac lymph nodes, consistent with radiopeptide therapy, including a hypodense isthmic thyroid nodule. Fine needle ultrasound-guided biopsy of the thyroid nodule was realized. Immunohistochemistry was positive for CD56, chromogranin, and synaptophysin and negative for calcitonin, confirming neuroendocrine tumor intrathyroid metastasis. 177Lu-DOTATATE SPECT/CT showed therapeutic uptake on the thyroid metastasis.

From the *Nuclear Medicine Department, Institut Universitaire de Cancérologie-Oncopole, Institut Claudius Regaud;

Nuclear Medicine Therapy Unit;

Radiology Department, Institut Universitaire de Cancérologie-Oncopole, Institut Claudius Regaud; and

§Pathology Department, CHU Toulouse, Toulouse, France.

Received for publication December 31, 2018; revision accepted March 2, 2019.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Lavinia Vija Racaru, MD, PhD, Nuclear Medicine Department, IUCT-Oncopole, Institut Claudius Regaud 1 Av. Irène Joliot-Curie, 31100 Toulouse, France. E-mail:

Online date: April 23, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.